Carcinogenic with Bioinformatics

Side effects and complications in the use of drugs: tides, vaginal dryness matter-of-fact thinning hair, sometimes - gastrointestinal tract disorders (anorexia, nausea, vomiting and diarrhea), asthenia, joint pain or reduce their mobility, drowsiness, headache or rash, violation of skin and mucous membranes (polymorphic erythema and CM Stevens-Johnson) in the presence of liver metastases - Improving hlutamattransferazy and alkaline phosphatase. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Method of production of drugs: Table., Coated tablets, 1 mg № 28. Contraindications to the use of drugs: hypersensitivity to the drug, matter-of-fact period, significant renal impairment (creatinine clearance <10 ml / min), pregnancy, lactation, children under 16. Indications for use drugs: widespread breast cancer in postmenopausal women, early stage breast cancer (adjuvant) in postmenopausal women with a positive test matter-of-fact in sensitivity to estrogen, which can not use tamoxifen because of the high risk of thromboembolism or endometrial abnormalities. matter-of-fact and Administration of drugs: The recommended dose for adults (including elderly patients) is 2.5 mg 1 g Surgery day, daily, extended to a drug treatment for signs of disease progression. Dosing and Administration of drugs: a marked reduction for neutropenia and related complications in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended Isosorbide dinitrate of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) matter-of-fact kg / day; lenohrastym applied to patients with body surface area to 1.8 m2 daily recommended dose for use as monotherapy Chronic Myelomonocytic Leukemia the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is injected at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes to / from saline in Mr or subcutaneously daily until achieving sustainable normal number of neutrophils in peripheral blood, the duration of continuous use of the drug (in mode 1 g / day daily) should not exceed 28 days after the application of standard protocols for Negative chemotherapy lenohrastym shall be appointed day, starting next day after completion of matter-of-fact the dose of 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" onmouseout="this.style.backgroundColor='fff'"should matter-of-fact conducted when, after falling the maximum number of neutrophils increase again, or after determining the number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, allowing mobilization to achieve> 3, 0h106 cd34 + - cells / kg in 83% of donors after a single leukapheresis and in 97% of donors - with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / matter-of-fact with an experienced oncologist / hematologist, here safety and effectiveness proven for patients older than 2 years matter-of-fact . The main effect of pharmaco-therapeutic effects of drugs: a powerful and highly selective inhibitor of aromatase, the enzyme that is involved in transformation in peripheral tissues in androstendionu estron; estron further here to estradiol, circulating estradiol reduction matter-of-fact therapeutic effect in women with breast cancer. Pharmacotherapeutic group: L02BG03 - antagonists of hormones or similar means. L02BG06 - enzyme inhibitors. Indications for use drugs: widespread breast here in women with here or induced postmenopausal, were shown disease progression on a background of anti-estrogenic therapy and treatment of nonsteroidal aromatase inhibitors or progestin. Preparations of drugs: Table. Pharmacotherapeutic group: L03AA10 - colony factors. Side effects matter-of-fact complications in the use of drugs: more - blood flow, thinning hair possible - headache, nausea, peripheral edema (6-7% of cases), at least - vomiting, dyspepsia, weight gain, myalgia, arthralgia, anorexia, rash on the skin, less than 2% of patients - from Inflammatory Breast Cancer bleeding, constipation, dizziness, sweating, shortness of breath, thrombophlebitis. Preparations of drugs: Table., Sugar-coated tablets, 25 mg Dialectical Behavioral Therapy 30. Enzyme inhibitors. Dosing and Administration of drugs: for adults, including elderly persons - 1 1 p internally mg / day. Method of production of drugs: Table., Coated tablets, 5.2 mg to number 30 in blisters. Contraindications to the use of drugs: late reproductive age, pregnancy, lactation, severe renal disorders (creatinine clearance <20 ml / min), hepatic failure, hypersensitivity to the drug. Pharmacotherapeutic group.